• Age ≥18 years of age on the day of consenting to the study.

• Patients must have histologically confirmed diagnosis of locally advanced intrahepatic cholangiocarcinoma

• Confirmed diagnosis of locally advanced unresectable iCCA with no vascular invasion, lymph node, or extrahepatic disease.

• Unresectable disease based on tumor location or underlying liver disease

• Patients must have ≥ 6 months of disease stability or tumor regression on neoadjuvant therapy. In cases in which patients had received second-line therapy, disease must also have been controlled for ≥ 6 months on that regimen.

• Patients who had previous surgical resection for iCCA are eligible if surgery occurred more than 6 months prior to listing, and patients have had ≥ 6 months of disease stability or response on therapy.

• ECOG performance status ≤1 (Karnofsky ≥70%, see Appendix A).

• Patients must have organ and marrow function acceptable for liver transplantation per institutional protocol:

• If history of chronic hepatitis B virus (HBV) infection, viral load should be undetectable on suppressive therapy.

• If history of chronic hepatitis C virus (HCV) infection, patients should have undetectable HCV viral load.

• Women of child-bearing years must have contraception plan in place from the time of study enrollment until at least one year following liver transplant.

• Ability to understand and the willingness to sign a written informed consent document

• Meets all other medical and psychosocial criteria for liver transplant

• Demonstrate ability to comply with study procedures